INCMOR 0208-301

Research code: INCMOR 0208-301
Research name: A multicentre, phase 3, randomised, double-blind, placebo-controlled research evaluating the efficacy and safety of tafasitamab plus lenalidomide in addition to rituximab compared with lenalidomide in addition to rituximab in patients with relapsed and refractory (R/R) grade 1-3a nodular lymphoma or R/R marginal zone lymphoma .
Indication: lymphoma
Principal researcher: Ewa Chmielowska, MD, PhD
Research population: patients with refractory nodular and marginal zone lymphoma
Research drug: tafasitamab + lenalidomide